- The VENTANA ALK (D5F3) CDx Assay(1) companion diagnostic is now indicated as an aid in identifying lung cancer patients eligible for treatment with three unique medicines.
Growth Capitalist (https://growthcapitalist.com/2017/11/roche-receives-fda-approval-for-ventana-alk-d5f3-cdx-assay-to-identify-lung-cancer-patients-eligible-for-treatment-with-roches-alecensa-alectinib/)
- The VENTANA ALK (D5F3) CDx Assay(1) companion diagnostic is now indicated as an aid in identifying lung cancer patients eligible for treatment with three unique medicines.